RE:RE:RE:Dr. Coombs and Covid
enriquesuave wrote: The potential could be enormous, but it's a long shot. If TLD-1433 could kill and neutralize any virus such as Covid or Influenza, then it could act as both a Therapeutic and Vaccine at the same time. IMO. Why, because an infected person would have dead inactivated virus in his body which would serve to stimulate an Immune Response much like a vaccine. No worries about mutations here, as it would not matter. I would suggest an inhaled form of TLD-1433 followed by a chest X-ray which could serve for diagnosing lung lesions and to further activate TLD-1433 killing more virus. ICAM protocol can also be added to reduce any possible cytokine storm. All IMO but Theralase should focus more on NMIBC and if they get Government grants for Viruses then let Dr Coombs advance this at the same time.
Agree...Just to add: I think the long shot potential will not be in the compound's viral killing capacity; its method of killing is scientifically undeniable, & such a killing mechanism allows it to act indiscriminately across viral strains...a huge treatment advantage over current antivirals. The long shot potential imo will be finding an effective/practical therapeutic form of compound delivery, which I also believe should either be in a nebulized or inhaler form...a nebulized form via mask delivery may actually be preferential in the earlier stages of illness. This would allow for more effective compound deposition in the upper airways, including one's nasal passages (where the viral load is highest at this stage). A post treatment sinus x-ray for early stages (in higher risk patients) & a chest X-ray performed in sicker patients (or those with symptoms of lower airway disease) would certainly provide a nice one-two punch : ).
As for investigating vaccine development (based on TLD-1433's mechanism of action), it's certainly an important goal to protect the vulnerable from infection in the first place. However, this type of development could be a much longer & more expensive investment imo. I'd rather get more bang for the buck & have TLT focus primarily on therapeutic development, relying heavily on grant monies. Such a novel breakthrough deserves our attention. The only resources TLT should have to contribute would be financial, & that should be limited based on the grant monies already awarded to Dr. Coombs lab...we just have to let the academic machine take over.
As for an effective/easy-to-use type of vaccine in the future, a nasal form would be desirable in regards to its ability to elicit a mucosal response (the first immune barrier of defense). It is also more kid/needle-averse friendly, especially for big kids like me. Good luck...